Biotech News

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics (ALGS)Aligos TherapeuticsClinical readout

ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activation Single and multiple ascending doses planned Study will allow rapid advancement into participants with chronic HBV infection in Q4 2026 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos

Related news

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

MISTMilestone Pharmaceuticals Inc.2026-10-09 12:00 EST

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

NAMSNewAmsterdam Pharma2026-09-29 12:00 EST

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

MLYSMineralys Therapeutics2026-10-09 13:00 EST

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

VKTXViking Therapeutics2026-09-22 11:05 EST

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

ALGSAligos Therapeutics2026-07-06 20:05 EST

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

MLYSMineralys Therapeutics2026-10-28 11:05 EST

Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

SGMTSagimet Biosciences2026-10-22 11:00 EST

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

VKTXViking Therapeutics2026-10-14 11:05 EST

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

Aligos Therapeutics

Liver and Viral Diseases Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production. Pevifoscorvir Sodium Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B...

Recent company news

Stock data

Close
1.25 USD
Market cap
32.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States